A low-energy total diet replacement program demonstrates a favorable safety profile and improves liver disease severity in nonalcoholic steatohepatitis

In NASH patients with obesity and fibrosis on a low-energy total diet replacement, LiverMultiScan cT1 detected significant reductions in liver disease activity. Compared to other NITs (CAP, MRE, VCTE), cT1 was the only consistent and reliable biomarker that captured change in liver disease severity, highlighting its utility for monitoring response to diet and lifestyle interventions.